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Abstract
Background: Epilepsy prevalence is over 20% for those with ID. It is difficult to di-
agnose and treat and more likely to be treatment resistant. The evidence informing 
prescribing is sparse, particularly for new drugs such as perampanel (PMP).
Aims of the Study: This study seeks to strengthen the research evidence regarding 
PMP for people with ID by pooling information from two isolated and separately con-
ducted studies: the UK-based Epilepsy Database Register (Ep-ID) and the data from 
the Kempenhaeghe clinic in the Netherlands.
Methods: A single data set of comparable data was created and analysed under 
agreement and supervision of a UK statistician.
Results: Seizure reduction within twelve months was evident in 62% of Dutch and 
47% of UK patients. Retention rates were higher for those in the UK (P = .01) and for 
patients with moderate to profound ID, whilst side effects were more prominent in 
the Dutch cohort.
Conclusions: Comparable rates of seizure reduction are in line with estimates for 
non-ID patients, adding to the evidence suggesting that PMP has a similar impact on 
those with ID. Taking a European perspective and sharing data across centres can 
help strengthen the evidence for prescribing antiepileptic drugs in the ID population.
K E Y W O R D S
behavioural health, co morbidity, Epilepsy, Intellectual disability, mental health, perampanel, 
physical health, seizures, UK Ep-ID Database Register
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1  | BACKGROUND
Epilepsy is a common health problem among people with an intel-
lectual disability (ID), with prevalence estimated around 22.2% and 
rates increasing with severity of ID.1 This is substantially higher than 
the reported prevalence of 1% in the general European population.2 
Epilepsy in the ID population is often more difficult to diagnose and 
treat, requires polypharmacy in many cases and is more likely to be 
treatment resistant.3,4 As antiepileptic drugs (AEDs) are the main-
stay of epilepsy treatment for preventing avoidable harm, it is im-
portant to ascertain the most relevant and appropriate medications. 
AEDs with new modes of action have been introduced in recent 
years, but patients with ID are usually excluded from the initial reg-
istration studies, due to both ethical and practical reasons. There is 
therefore limited evidence to inform AED prescribing in people with 
epilepsy and ID.4,5
Perampanel (PMP), is a non-competitive α-amino-3-hy-
droxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antag-
onist. PMP was accepted in 2012 as an add-on AED for focal-onset 
seizures in patients aged twelve years or above by the European 
Medicines Agency (EMA). Initial registration studies were followed 
by observational studies focussing on clinical experience, which 
confirmed the efficacy and safety of PMP in people with refractory 
epilepsy.6-8
Evidence regarding the clinical experience of PMP in people 
with ID and epilepsy is limited. A multicentre retrospective case 
note review UK study, which included a sub-group of people 
with ID (86 of the total 310 patients), showed no difference in 
dropout rates, efficacy and side effects from the general popula-
tion.9 Another retrospective UK study compared mild and moder-
ate-severe ID populations with those who have epilepsy from the 
general population (also through medical records review) and re-
ported findings supporting the safe use of PMP for those with ID, 
along with indicators of higher tolerability and efficacy for those 
with moderate to profound ID compared to mild ID.10 Behavioural 
side effects were however cited in the 73 ID patients (from the 
total cohort of 144) particularly in those with a previous history 
of mental health or behavioural concerns, and this was also ap-
parent in two additional European studies,11,12 with a Dutch study 
reporting sides effects in 40.3% of 62 ID patients11 and a German 
study of 27 patients suggesting caution should be considered for 
PMP use in those with ID and known psychiatric conditions or be-
havioural problems.12 Both the Dutch and German studies focused 
exclusively on ID populations. The growing evidence base is how-
ever small, and more in-depth clinical guidance for this vulnerable 
population is required.13,14
2  | AIMS OF THE STUDY
To build the research evidence regarding the use of PMP in peo-
ple with ID, by pooling and comparing data sets from two of the 
European studies detailed above.
3  | METHODS
A UK and Dutch collaboration has been set up to draw findings 
from the UK-based Epilepsy Database Register (Ep-ID)10 and the 
data from the Kempenhaeghe clinic, a tertiary epilepsy centre.11 
The paper also looks to provide insight into the possibilities for such 
cross-national work.
Data collected, recruitment processes and research methodol-
ogies employed for both the UK and Dutch studies, are detailed in 
Supporting Information S1. Work was completed to synchronize the 
two data sets (Supporting Information S1). A single data set of com-
parable data was then created. This detailed 12 months of clinically 
recorded data relating to the use of PER in both patient popula-
tions. An expert UK statistician (WH) ensured suitable homogeni-
zation of the data set to allow appropriate and direct comparison of 
the two cohorts. It also allowed for certain data to be pooled and 
analysed. All data remained confidential and anonymous. Both data 
sets at time of collection had relevant ethics approvals.
Adverse effects, dropout rates, seizure type and frequency were 
estimated separately for the UK, Dutch cohorts and for the com-
bined data. Comparisons of outcomes in the mild and moderate to 
F I G U R E  1   Forest plots showing risk ratios (RR) for differences 
in retention, efficacy and side effects between mild and moderate 
to profound ID. RRs of greater than 1 indicate a higher risk of the 
outcome for moderate to profound ID. Pooled estimates are shown 
based on a fixed-effects model
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profound ID groups were made using fixed and random effects me-
ta-analysis in the R software environment for statistical computing 
(with the ‘meta’ package). Heterogeneity between studies was as-
sessed using the I2 statistic. Comparisons of overall outcome rates in 
the UK and Dutch data were made using Fisher's exact test.
The homogenization ensures wherever possible that the inclu-
sion/exclusion criteria for the two populations were comparable and 
that the variables in the two data sets had consistent definitions, 
with measurements taken at the same time points such as having 
consistency in the population examined and the diagnosis. Details 
are given in Supporting Information S1.
Analysis is presented for the individual studies to allow compar-
isons with the results from the original papers and to highlight dif-
ferences between the studies. The method of pooling used for the 
analysis was a fixed effects meta-analysis.15 This assumes the under-
lying effect is the same in the two studies, and the observed effects 
differ because of sampling variation. The random effects model as-
sumes each study estimates a different underlying true effect, and 
these effects have a distribution. There is expected considerable 
heterogeneity between these two separately conducted studies in 
terms of demographic and clinical characteristics. The I2 statistic is a 
measure of how much heterogeneity there is between studies with 
values close to 0% indicating low heterogeneity and values of over 
75% corresponding to high heterogeneity. All analyses were con-
ducted using the statistical software R.
4  | RESULTS
The aim of this study was to explore whether there was potential for 
pooling information from the studies. Pooled response data are pre-
sented in Table 2 for descriptive purposes. Further analysis revealed 
little evidence of study heterogeneity when comparing responses 
across ID sub-groups (indicated by the low I2 values in Table 3). For this 
reason, it was decided to present a formal pooled analysis of ID sub-
group differences in retention, efficacy and side effects in Figure 1.
4.1 | Demographics and clinical data
Patient demographics and key clinical data from both studies are 
detailed in Table 1. Study heterogeneity was identified from the de-
mographic and clinical data. Variations in the age of participants (UK 
mean 43.3 years vs Dutch mean 36.2 years) and sex (UK females 
48% vs 33%) were apparent. More of the UK cohort had mild ID 
(66%), compared to a 50% split in the Dutch group. Seizures types 
were different with UK Generalized 56%, Focal 44% compared to 
Dutch 25.8% and 74.2%
Starting dose was 2 mg for adult patients in both cohorts. 
Maximum dosage used for patients was similar (UK 5.82 mg and 
Dutch 5.6 mg).
There were also differences in seizure type with 56% of UK patients 
but only 21% of Dutch patients having seizures defined as “generalized.”
4.2 | Response to perampanel
Twelve month summative data regarding efficacy, tolerance, reten-
tion and side effects associated with PMP for UK and Dutch patients 
TA B L E  1   Demographic and clinical data
UK Study Dutch Study
Age Mean = 43.3 y Mean = 36.2 y
SD = 14.7 SD = 13.7
Age at onset Mean = 12.3 y Mean age at 
onset = 7.4 y
Sex Male—38 (52%) Male—28 (67%)
Female—35 (48%) Female—14 (33%)
ID type Mild—48 (66%) Mild—21 (50%)










Starting dose 2 mg Starting dose 
adult—2 mg
Mean Max—5.82 mg Mean Max 6.5 mg






Sample size, n 73 42 115
Seizure reduction 47% 62% 53%
Retention 77% 52% 68%
Side effects
Mental health 19% 52% 31%
Physical health 27% 48% 35%
Mild ID
Sample size, n 48 21 69
Responder rate 44% 62% 50%
Retention 69% 43% 61%
Side effects
Mental health 17% 52% 28%
Physical health 33% 48% 38%
Moderate to profound ID
Sample size, n 25 21 46
Responder rate 52% 62% 57%
Retention 92% 62% 78%
Side effects
Mental health 24% 52% 37%
Physical health 16% 48% 30%
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are detailed in Table 2. Data for both ID groups are also pooled in 
this table. Figure 1 shows forest plots summarizing differences in 
outcomes between ID sub-groups in both studies and for pooled 
data from both studies. Pooled estimates are shown based on a fixed 
effects model but consistent results were found using a random ef-
fects model. The level of heterogeneity across studies is quantified 
using the I2 statistic in Table 3.
Recorded rates of seizure reduction were lower in the UK pop-
ulation with just under half of UK participants (47%) appearing to 
benefit from a reduction in seizures by 12 months, whilst in the 
Netherland population this was 62%. Seizure reduction was a de-
scriptive measure, defined by a clinically documented decrease in 
seizure frequency. These differences were not however statistically 
significant (P = .2). There was also no statistical significance when ID 
groups were compared within studies or when the data were pooled 
(RR of response for moderate to profound versus mild ID: 1.09, 95% 
CI 0.77-1.54).
Despite similarities in seizure reduction, there is significant varia-
tion in retention rates, with only half (52%) of Dutch patients remain-
ing on PMP after 12 months, but over three quarters (77%) of the UK 
patients still taking PMP (P = .01). However, there was no evidence 
of study heterogeneity when comparing retention across ID groups 
(I2 = 0; P = .8). Both studies indicate that those with severe/profound 
ID have higher retention rates (RR of response for moderate to pro-
found versus mild ID: 1.37, 95% CI 1.08-1.73).
Side effects were reported more prominently in the Dutch pa-
tient cohort, for both mental health/behavioural (52% Dutch, 19% 
UK; P < .001) and physical health side effects (48% Dutch, 27% UK; 
P = .04). There was no evidence of variation between mild and mod-
erate/profound ID groups in the level of physical or mental health 
side effects in each study and when study cohorts are combined 
(Figure 1).
5  | CONCLUSIONS
The decline in seizure frequency for ID patients who have been pre-
scribed PMP reported in this paper is similar to data reported for 
non-ID patients in three (phase III) drug trials.6,7,9 This adds to the ev-
idence suggesting that PMP has a similar impact on seizure reduction 
for people with adult pharmacoresistant epilepsy with or without ID.
Our data indicate that despite the comparable reports of seizure 
reduction in our UK and Dutch ID patient cohorts, retention rates 
are statistically different. Discontinuation has been linked to side 
effects for the Dutch cohort previously,11 and the data reported in 
this paper highlight the significantly higher number of reported side 
effects (physical and mental) when the Dutch cohort is compared 
with those from the UK. Fewer reported side effects in the UK co-
hort may therefore have some impact on the higher retention rates 
for PMP. This could be due to slower titration patterns in the UK for 
people with ID.10,16
Pooling data from the two studies and comparing ID groups 
has indicated that people with severe/profound ID may have 
higher retention rates than those with mild ID. This trend is appar-
ent despite similarities in reported-side effects across ID groups in 
both settings, indicating that in this instance there is no evidence 
to suggest side effects are of such significance to impact retention 
in this sub-group.
There are limitations with this study. Data collected from medical 
records at each site were dependent on the quality and accuracy of 
clinical data recorded and available to be captured. Each study in-
volved people treated by different clinicians and in the UK at a num-
ber of different institutions. Clustering by clinician/institution was 
not considered. Differences in side effects such as mental health 
side effects may for example relate to how often each individual 
was seen at each institution and how much depth of information is 
sought and also recorded by Clinicians.
Diagnosis in both settings was completed by Dutch and UK spe-
cialists following the ILAE criteria. However, diagnosing seizures 
in people with ID is challenging and likely to have higher levels of 
error than in general population. Particularly, there may have been 
discrepancies in diagnosing sub-types which may explain the large 
differences reported regarding general verses focal seizures, such 
as complex partial seizures with secondary generalization as versus 
idiopathic generalized epilepsy in people with ID. Further, many peo-
ple with ID have multiple seizure types not to mention behavioural or 
neuromuscular issues which can further confound the picture. Thus, 
it was felt that we look to capture "epilepsy" or "seizures" principally.
The UK data are also confined to individuals who consented to 
access to their medical records to be included in a research database. 
Dutch patients may choose to consent to use of their data when 
becoming a patient with the centre. Confounders include possibility 
of slower titration and that in the UK people with ID are community 
based whilst majority of the Dutch ID sample are supported in an 
institutional model. Our analyses of demographic and clinical char-
acteristics suggested the presence of considerable heterogeneity 
Outcome
Heterogeneity (I2) for 
comparison of ID groups
Test for difference in outcome rates 
between studies (UK vs Dutch data)
Efficacy 0% (P = .7) 47% vs 62% (P = .2)
Retention 0% (P = .8) 77% vs 52% (P = .01)
Physical health side 
effects
39% (P = .2) 27% vs 48% (P = .04)
Mental health side 
effects
0% (P = .5) 19% vs 52% (P < .001)
TA B L E  3   Response to perampanel—
comparison of studies
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between studies. There is no accepted statistical approach to me-
ta-analysis of only two studies in the presence of heterogeneity.14
The study however illustrates how taking a European perspec-
tive and sharing anonymous data across centres offers the possi-
bility for strengthening evidence around the prescribing of AEDs in 
complex and difficult to research populations, such as those with ID 
and epilepsy. Comparing the Dutch and UK data by combining data 
sets for deeper analysis furthers discussion around positioning the 
use of PMP with ID populations.
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